Profile data is unavailable for this security.
About the company
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
- Revenue in EUR (TTM)0.00
- Net income in EUR-14.76m
- Incorporated2006
- Employees19.00
- LocationGeneuro SA3, Chemin du Pre-FleuriPLAN-LES-OUATES 1228SwitzerlandCHE
- Phone+41 225524800
- Fax+41 227945086
- Websitehttps://www.geneuro.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Poxel SA | 1.55m | -44.24m | 29.68m | 30.00 | -- | -- | -- | 19.20 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
Global Bioenergies SA | 3.25m | -8.66m | 33.19m | 46.00 | -- | 3.19 | -- | 10.22 | -0.4797 | -0.4797 | 0.1802 | 0.5743 | 0.1632 | 5.21 | 65.62 | 70,638.05 | -43.47 | -43.66 | -64.54 | -82.47 | -153.20 | -948.35 | -266.41 | -1,331.36 | 3.54 | -- | 0.2626 | -- | 365.83 | 36.25 | 27.78 | -- | -19.49 | -- |
Fermentalg SA | 4.06m | -14.15m | 33.24m | 62.00 | -- | 1.02 | -- | 8.19 | -0.3176 | -0.3176 | 0.0917 | 0.6033 | 0.0753 | 0.533 | 3.35 | 65,451.61 | -24.63 | -21.94 | -26.79 | -24.71 | 13.21 | 14.73 | -327.08 | -248.95 | 3.53 | -60.94 | 0.3323 | -- | -46.94 | 75.18 | -43.29 | -- | -10.93 | -- |
Abionyx Pharma SA | 4.64m | -3.52m | 35.38m | 61.00 | -- | 4.43 | -- | 7.63 | -0.121 | -0.121 | 0.1581 | 0.246 | 0.3027 | 21.86 | 4.20 | 76,694.22 | -22.95 | -18.82 | -32.52 | -28.87 | 13.32 | 14.32 | -75.82 | -128.54 | 1.70 | -- | 0.2997 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
Groupe Berkem SA | 51.94m | 367.00k | 38.73m | 200.00 | 105.57 | 1.39 | 8.71 | 0.7457 | 0.0207 | 0.0207 | 2.92 | 1.57 | -- | -- | -- | 259,720.00 | -- | -- | -- | -- | 55.32 | -- | 0.7065 | -- | 0.8988 | 1.36 | 0.5798 | -- | 0.733 | -- | 123.42 | -- | -- | -- |
genOway SA | 18.63m | 1.59m | 39.88m | 124.00 | 23.71 | 2.34 | 9.94 | 2.14 | 0.1814 | 0.1814 | 2.12 | 1.84 | 0.5813 | 0.3881 | 2.50 | 142,180.80 | 4.98 | -0.5615 | 6.72 | -0.8058 | 97.61 | 93.72 | 8.56 | -1.12 | 2.10 | 17.42 | 0.3344 | -- | 21.64 | 11.57 | 341.09 | -16.63 | -18.02 | -- |
Gensight Biologics SA | 1.27m | -26.22m | 40.14m | 16.00 | -- | -- | -- | 31.68 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
Biosynex SA | 93.05m | -13.79m | 41.54m | 560.00 | -- | -- | -- | 0.4464 | -1.94 | -1.94 | -- | -- | -- | -- | -- | 248,141.30 | -- | 25.60 | -- | 33.90 | 25.22 | 51.82 | -13.15 | 20.26 | -- | -4.45 | -- | 14.72 | -48.61 | 45.12 | -84.99 | 118.26 | -- | -- |
AbL Diagnostics SA | 11.19m | 1.20m | 48.99m | 19.00 | 5.07 | 7.30 | 161.45 | 4.38 | 0.5997 | 0.5997 | 5.58 | 0.4165 | 1.18 | -- | 5.21 | 588,990.50 | 12.67 | 8.99 | 26.09 | 10.77 | 35.76 | 38.29 | 10.75 | 31.17 | 1.28 | -- | 0.31 | 0.00 | -- | 67.89 | 328.77 | -- | -- | -- |
GeNeuro SA | 0.00 | -14.76m | 55.06m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
Valbiotis SA | 4.73m | -7.37m | 65.15m | 52.00 | -- | 3.32 | -- | 13.77 | -0.5904 | -0.5904 | 0.3798 | 1.24 | 0.1564 | 3.36 | 17.83 | 91,019.23 | -24.35 | -32.92 | -33.77 | -46.36 | 48.76 | 53.15 | -155.67 | -418.87 | 3.38 | -38.19 | 0.2598 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
AFYREN SA | 3.38m | -9.59m | 69.74m | 122.00 | -- | 1.13 | -- | 20.64 | -0.3696 | -0.3696 | 0.1303 | 2.37 | 0.0435 | -- | 5.39 | 27,696.72 | -12.35 | -9.58 | -13.42 | -10.46 | 92.63 | 95.57 | -283.69 | -162.61 | -- | -1.62 | 0.0719 | -- | -2.23 | -- | -4.20 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Financi�re Arbevel SAas of 30 Dec 2022 | 415.58k | 1.40% |
Invesco Advisers, Inc.as of 31 Dec 2023 | 34.89k | 0.12% |
Aviva Investors Global Services Ltd.as of 15 Apr 2021 | 21.35k | 0.07% |